$0.70—Stale · unknown old
XETRA • Last print unknown ago
$0.70—Stale · unknown old
Epigenomics AG specializes in the development of molecular diagnostics for cancer detection, particularly focusing on blood-based tests for colorectal cancer. The company operates primarily in Germany and has a unique competitive advantage with its proprietary technology for DNA methylation analysis, which enhances the accuracy of cancer diagnostics.
Epigenomics generates revenue primarily through the sale of its proprietary diagnostic tests, which leverage advanced DNA methylation technology. The company benefits from high gross margins due to the specialized nature of its products and limited competition in the niche market of blood-based cancer diagnostics.
Approval of new diagnostic tests by regulatory bodies such as the FDA or EMA
Partnerships with healthcare providers or pharmaceutical companies
Market adoption rates of colorectal cancer screening tests
Changes in reimbursement policies for diagnostic tests
Regulatory changes that could impact the approval process for new diagnostic tests
Technological advancements by competitors that could render current products obsolete
Emergence of alternative cancer detection technologies, such as liquid biopsies
Increased competition from larger diagnostic firms entering the colorectal cancer market
Negative operating cash flow could strain liquidity if not addressed
Dependence on a single product line increases vulnerability to market shifts
moderate - The demand for diagnostic tests is somewhat correlated with overall healthcare spending, which can be influenced by GDP growth.
Interest rates have a minimal direct impact on Epigenomics since the company is not heavily reliant on debt financing. However, higher rates could affect healthcare spending indirectly.
minimal - The company has a low debt-to-equity ratio (0.08), indicating limited reliance on credit.
growth - Investors looking for exposure to innovative healthcare solutions and potential breakthroughs in cancer diagnostics.
high - The stock has exhibited significant volatility, with a 1-year return of -82.1%, indicating high risk.